Moderna and Merck announced their cancer vaccine extended melanoma remission in a late-stage trial. The stocks jumped. Retail traders saw the headline and bought both. They will lose money.
The combination therapy performed better than Keytruda alone. Keytruda is already an approved treatment. So the news is that adding something to an existing drug makes it work better. Groundbreaking stuff. Next they'll discover that two tires work worse than four.
Here's what happened in every brokerage account this morning. Guy sees "cancer vaccine" and "soars" in the same headline. Doesn't read past the word promise. Market buys MRNA at the absolute top. Sets a mental stop loss. Forgets about the mental stop loss. Checks his phone at lunch. Down 8%. Holds anyway because he read on Reddit that diamond hands are a personality trait.
The trial data matters to oncologists. It matters to melanoma patients. It does not matter to the stock price four trading days from now. But some guy named Brett just put his kid's 529 plan into pharmaceutical stocks because he thinks he cracked the code. Brett's code is reading CNBC headlines and clicking buy. Brett's daughter is going to community college.
Technical analysts looked at the chart. Saw a gap up. Noted the volume spike. Ignored the news entirely. Made money on the reversion. They will make money again when it fades. They always do.
The funniest part is watching traders convince themselves they're investing in medical innovation. You're not funding research. You're buying shares from someone smarter at 9:47 AM and selling them to someone dumber at 2:15 PM. Moderna already has your money. They spent it on the trial that finished before you woke up today.
Brett's checking premarket quotes tomorrow wondering why his life-saving cancer breakthrough is red.
Photo by on Unsplash
Leave a Comment